Effect of the potent aromatase inhibitor fadrozole hydrochloride (CGS 16949A) in postmenopausal women with breast carcinoma
Open Access
- 1 January 1999
- Vol. 85 (1) , 100-103
- https://doi.org/10.1002/(sici)1097-0142(19990101)85:1<100::aid-cncr14>3.0.co;2-5
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: Results of two randomized double blind controlled multiinstitutional trialsCancer, 1996
- Tamoxifen and toremifene lower serum cholesterol by inhibition of delta 8-cholesterol conversion to lathosterol in women with breast cancer.Journal of Clinical Oncology, 1995
- Tamoxifen decreases serum cholesterol by inhibiting cholesterol synthesisAtherosclerosis, 1992
- Effects of Tamoxifen on Bone Mineral Density in Postmenopausal Women with Breast CancerNew England Journal of Medicine, 1992
- Effects of Tamoxifen on Cardiovascular Risk Factors in Postmenopausal WomenAnnals of Internal Medicine, 1991
- Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee.BMJ, 1991
- Specificity of Low Dose Fadrozole Hydrochloride (CGS 16949A) as an Aromatase InhibitorJournal of Clinical Endocrinology & Metabolism, 1991
- Inhibition of Aromatase With CGS 16949A in Postmenopausal Women*Journal of Clinical Endocrinology & Metabolism, 1989